Overview of Humira® Biosimilars: Current European Landscape and Future Implications
Author:
Funder
National Institutes of Health
Publisher
Elsevier BV
Subject
Pharmaceutical Science
Reference55 articles.
1. Top companies and drugs by sales in 2019;Urquhart;Nat Rev Drug Discov,2020
2. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases;Billmeier;World J Gastroenterol,2016
3. Infliximab biosimilars in the age of personalized medicine;Kang;Trends Biotechnol,2018
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective;Journal of Medical Economics;2024-07-23
2. Clinical outcomes of switching to adalimumab biosimilar (MSB11022) in patients with rheumatoid arthritis: RESTART Spanish Registry;Current Medical Research and Opinion;2024-07-04
3. Pharmaceutical and biotech industry perspectives on optimizing patient experience and treatment adherence through subcutaneous drug delivery design;Advanced Drug Delivery Reviews;2024-06
4. Challenges for further successful development of tumor necrosis factor targeting therapies for uveitis;Expert Opinion on Investigational Drugs;2024-02
5. Golimumab and certolizumab pegol for the treatment of hidradenitis suppurativa: a literature review and future perspective;Therapeutic Advances in Chronic Disease;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3